1.Pérez Avila J, Pérez Correa D, González Nuñez I, Díaz Jidy M, Millan marcelo JC, Orta M. Pautas Cubanas para el tratamiento y manejo de los pacientes VIH/SIDA sometidos a Terapéutica Antirretroviral, 2000. 2.Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): The Fisrt 10 Years. Blood, vol 88(6): 1907-1929, 1996. 3.DR Kuritzkes. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocytic colony-stimulating factor. Clin Infect Dis 2000 Feb; 30 (2): 256-60. 4.Giralt M Neutropenias y agranulocitosis. En: Sans-Sabrafen J. Hematología clínica (3.a ed.). Barcelona: Mosby-Doyma Libros S.A., 1994; 262-272. 5.Foucar K, Duncan MH, Smith K Practical approach to the investigation of neutropenia. Clin Lab Med 1993; 13: 879-894. 6.Sommelet D Conduite à tenir devant une neutropénie. Arch Pediatr 1998; 5 (Supl 2): 120-130. 7.Boxer LA, Blackwood RA Leukocyte disorders: quantitative and qualitative disorders of the neutrophil (parte 1). Pediatr Rev 1996; 17: 19-28 8.Referencia de Escala Toxicidad OMS: World Health Organization (1979). Handbook for reporting results of cancer treatment, pp. 15-22. WHO, Geneva. 9.Referencia de Evaluación de Estado Clínico según Criterios OMS: Oken,MM; CEIech, R.H; Thormey,D.C et al: Am J Clin Oncol 5: 649- 655, 1982. 10.Cairo MS. Review of G-CSF and GM-DSF effects on neonatal neutrophil kinetic. American Journal of Pediatric Hematology/Oncology 11: 238-244, 1989. 11.Demetri GD, Griffin JD. Granulocyte colony stimulating factor and its receptor. Blood 78: 2791, 1991. 12.Inazawa J, Fukanaga R, Seto Y, Nakagawa H, Misawa S, Abe T, Nagata S. Assignment of the human granulocyte colony stimulating factor receptor gene (CSF3R) to chromosome 1 at region p35-p34.3. Genomics 10: 1075, 1991. 13.Bashey A, Healy, Marshal CJ. Proliferation but not nonproliferative response to granulocyte colony stimulating factor are associated with rapid activation of the p21ras/MAP kinase signalling pathway. Blood 83: 949, 1994. 14.Nicholson SE, Novak U, Ziegler SF, Layton JE. Distinct regions of the granulocyte colony stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Blood 86: 3698, 1995. 15.Tweardy DJ, Wright TM, Ziegler SF, Bauman H, Chakraborty A, White SM, Dyer KF, Rubin KA. Granulocyte colony stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells. Blood 86: 4409, 1995. 16.Rauprich P, Kasper B, Tidow N, Welte K. The protein tyrosine kinase JAK2 is activated in neutrophils from patients with severe congenital neutropenia. Blood 86: 4500, 1995. 17.Clark SC, Kamen R. The human hematopoietic colony stimulating factors. Science 236: 1229-1237, 1987. 18.Ulich TR, Castillo J, Souza L. Kinetics and mechanism of recombinat human granulocyte colony stimulating factor induced neutrophilia. American Journal of Pathology 133: 630-638, 1988. 19.Vellenga E, Rambaldi A, Ernst TJ, Ostapovicz D, Griffin JD. Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood 71: 1529-1532, 1988. 20.Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, et al. The suppressive influence of human tumor necrosis factor on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis J, Picozzi V, Rausch G, Smith R, Gandishar W, Yahanda A, Vincent M, Stewart M, Glspay J. Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patient with small cell lung cancer. N Engl J Med 325: 164, 1991. 21.Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemier U, Lebeau B, Depierre A, johnson P, Decoster G, Tomita D, Ewen C. Recombinant granulocyte colony stimulating factor reduce the infectious complication of cytotoxic chemotherapy. Eur J Cancer 29a: 319, 1993. 22.Masuda N, Fukoka M, Furuse K. CODE chemotherapy with or without recombinant human granulocyte colony stimulating factor in extensive stage small cell lung cancer. Semin Oncol 49: 19, 1992. 23.Fukoka M, Masuda N, Takada M, Kodama N, Kawahara M, Furuse K. Dose intensive chemotherapy in extensive stage small cell lung cancer. Semin Oncol 21:43, 1994. 24. Bronchud MH, Scarffe JH, Thatcher N, et al: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809-813, 1987. 25.Maugard-Louboutin C, Chastang C, Chevallier B, et al: Dose-effect relationship of granulocyte colony stimulating factor (G-CSF): PE 2601 in patients (pts) with advanced breast carcinoma (ABC) treated by intensive chemotherapy. Proc Am Soc Clin Oncol 12:90, 1993. 26. Eguchi K, Shinkai T, Sasaki Y, et al: Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer. Jpn J Cancer Res 81:1168-1174, 1990. 27. Eguchi K, Sasaki S, Tamura T: Dose escalation study of recombinant human granulocyte colony-stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Res 49:5221-5224, 1989. 28. Kaneko T, Takaku F, Ogawa M: Outline of clinical studies on recombinant human granulocyte colony stimulating factor (KRN 8601) in Japan. Tokai J Exp Clin Med 16:51-61, 1991. 29. DÅhrsen U, Villeval JL, Boyd J, et al: Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074-2081, 1988. 30.Sheridan W, Begley G, Juttner C, et al: Effect of different doses and schedules of r-metHuG-CSF (filgrastim) dose on mononuclea r cell and PBPC collections and haematopoietic recovery after high dose chemotherapy (HDC) and infusion of r-metHuG-CSF mobilized peripheral blood progenitor cells (PBPC) without bone marrow. Blood 80:331a, 1992. 31.Sheridan W, Begley G, Juttner C, et al: The impact of r-metHuG-CSF (filgrastim) dose on the mobilisation of mononuclear and progenitor cells in peripheral blood in patients with malignancy. Blood 80:420a, 1992. 32.Negrin RS, Haeuber DH, Nagler A, et al: Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A phase I-II trial. Ann Intern Med 110:976-984, 1989. 33.Negrin RS, Haeuber DH, Nagler A, et al: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36-43, 1990. 34.Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988 35.Fukuoka M, Takada M, Masuda N, et al: Dose intensive weekly chemotherapy (CT) with or without recombinant human granulocyte colony-stimulating factor (G-CSF) in extensive-stage (ES) small-cell lung cancer (SCLC). Proc Am Soc Clin Oncol 11:290, 1992. 36.Kudoh S, Fukuoka M, Negoro S, et al: Weekly dose-intensive chemotherapy in patients with small-cell lung cancer: a pilot study. Am J Clin Oncol 15:29-34, 1992. 37.Ogawa M, Masaoka T, Takaku F: Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy for malignant lymphomas. Proc Am Soc Clin Oncol 9:76, 1990. 38.WWW.UNAIDS.ORG 39.Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis. 2000 Feb; 30 (2): 256-60. 40.Kuritzkes DR. Clinical experience with Filgrastim in AIDS. J Hematother Stem Cell Res. 1999: 8 Suppl 1: S17-9 41.Davidson M, Min YI, Holbrook Jt, Van Natta ML, Murphy R, Jabs DA et al. Use of filgrastim as adjuvant therapy in patients with AIDS-related cytomegalovirus retinitis. AIDS 2002 Mar 29; 16 (5): 757-65. 42.Feregrino-Goyos M, Gallegos P H, Eid-Lidt G y Alvarado-Diez R. Terapéutica de la Leucopenia del SIDA con factores estimulantes de colonias de granulocitos (FECG) y de granulocitos macrófagos (FECGM). 1993. No. 381. IV Congreso Nacional Sobre SIDA 1993. 43.Alvarado-Diez R, Feregrino-Goyos M, Eid-Lidt G y Gallegos P H. AIDS neutropennia management with colonies stimulating factors (GMCSF and GCSF). 1994. No. 702. X Conferencia Internacional Sobre SIDA; Yokohama 1994. 44.Valencia ME, Moreno V, Soriano V, Polo R, Verdejo J, Laguna F et al. Colony-stimulating-factors and HIV-related neoplasms. An. Med Interna 1996; Vol. 13 (7): 317-21. 45.45Centers for disease control. Update on acquired immune deficiency syndrome (AIDS)-United Status. MMWR 1982; 31: 507-8, 513-14. 46.Centers for disease control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting-United Status. Ann Intern Med 1985; 103: 402-3. 47.Biggar RF, Engels EA, Frisch M, Goedert JJ. Risk of T cell lymphomas in persons with AIDS. J AIDS 2001; 26: 371-6. 48.Cote TR, Biggar RF, Rosenberg PS, et al. Non -Hodgkin's Lymphoma among people with AIDS: incidence, presentation and public health burden . Int J Cancer 1997; 73: 645-50. 49.Hernández GE, Gómez X, Villasís A. Linfomas no-Hodgkin asociados a SIDA: evolución durante los 20 años de la pandemia y Experiencia en el INCMNSZ. Rev Invest Clín 2004; Vol. 56(2):186-192 50.Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 31: 81-7. 51.Little RF, Pittaluga S, Grant N, Steinberg SM, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101(12): 4653-9. 52.Remick SC, Sedransk N, Haase RF, Blanchard CG, Ramnes CR, Nazeer T et al. Oral combination chemotherapy in conjunction with filgrastim (GCSF) in the treatment of AIDS-related non-Hodgkin’s lymphoma: evaluation of role of GCSF; quality-of- life analysis and long-term follow-up. Am J Hematol. 2001 Mar; 66 (3): 178-88. 53.Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN and Ratner L. Chemotherapy consisting of doxorubicin, bleomycin, Vinblastine and Dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: a prospective , multiinstitutional AIDS clinical trials group study (ACTG 149). J Adquir Immune Defic Syndr. 2000 Aug 15; 24 (5): 444-50. 54.Orem J, Fu P, Ness A, Mwanda WO and Remick SC. Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin’s disease. East Afr Med J. 2005 Sep; 82 (9 supl): S144-9. 55.Gill PS, Mitsuyasu RT, Montgomery T, Huang J, Cabriales S, Testa M et al. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma. Cancer J Sci Am. 1997 Sep-Oct; 3(5): 278-83. 56.Dubreuil-Lemaire ML, Gori A, Vittecoq D, Panelatti G, Tharaux F, Palisses R et al. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients. Eur J Haematol. 2000 Nov; 65 (5): 337-43. 57.Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, Mallon KP et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS. 1998 Jan 1; 12 (1): 65-74. 58.Levine JD, Allan JD, Tessitore JH, Falcone N, Galasso F, Israel RJ et al. Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Ameliorates Zidovudine-Induced Neutropenia in Patients With Acquired Immunodeficiency Syndrome (AIDS)/AIDS-Related Complex. Blood 1991; Vol 78, No 12: pp 3148-3154. 59.Holmes F, Jones S, Shaughnessy J, Vukelja S, George T et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Annals of Oncology 13:903-909, 2002. 60. Stull D, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim ang filgrastim in teh treatment of chemotherapy-induced neutropenia. Am J Health-Syst Pharm 62: 83-7, 2005. 61.Wilford M, Fernández J, Mesa R, Muñio J, Figueredo I, Luna C, Prieto L, Piedra P, Mendoza I, Izquierdo M, Robaina M, Catalá M. “Evaluación clínica y seguridad del ior G-CSF en pacientes con neutropenia grado III-IV por quimio y/o radioterapia. Estudio de extensión”. HM-103: ISBN 959-7164-88-4, V Congreso Nacional. VII Jornada Latinoamericana de Hematología, Inmunología y Medicina Transfusional. 16-20/Mayo/2005. 62.Tsukadaira A., Okubo Y., Takashi S., Kobayashi H., Kubo, K. Repeated arthralgia associated with granulocyte colony stimulating factor administration Ann Rheum Dis 2002; 61:849–850. 63.Dana W. Assessing the relevante of outcomes data of colony-stimulating factors. J Managed Care Pharm 6 (2):144-150, 2000. 64.Sánchez GA, Cervantes G y Maldonado JS. Linfomas no Hodgkin. Artículo de revisión. Med Int Mex 2004; 20: 111-23. 65.Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS related lymphoma. Blood 2000; 96: 4084-90. 66.Matthews GV, Bower M, Mandalia S, Ponles T, Nelson MR, Gazzard BG. Changes in AIDS related lymphoma since the introduction of highly active anti-retroviral therapy. Blood 2000; 96: 2730-4. 67.Rabkin Cs, Yang Q, Goedert JJ, et al. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1 infected individuals. Blood 1999; 93: 1838-42. 68.Dean M, Jacobson LP, McFarlane J, et al. Reduced risk of AIDS lymphoma in individuals hetorocygous for the CCR5- D32 mutation. Cancer Res 1999; 59: 3561-4.